SCHEMBL20818253

SCHEMBL20818253

CC(C)(C)OC(=O)CN1CCN(c2c(Br)cn[nH]c2=O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPC5 Q9UL62 6/20 0.37
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ POLB P06746 2/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ CHRM4 P08173 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34
▸ PLA2G10 O15496 1/20 0.34
▸ PLA2G5 P39877 1/20 0.34
▸ AURKA O14965 1/20 0.33
▸ IDO1 P14902 1/20 0.32
▸ TDO2 P48775 1/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818351 0.83 KCNH2 (0.44) ALDH1A1CHRM2CHRM4CHRM1CHRM3
SCHEMBL31108113 0.74 GPR119 (0.43) ALDH1A1KDM4ESMN1; SMN2TIPARP
SCHEMBL25237273 0.73 TRPC5 (0.39) TRPC5ALDH1A1POLBIDO1TDO2
SCHEMBL3799622 0.71 PLA2G10 (0.41) ALDH1A1KDM4EWNT1GSK3BDYRK1A
SCHEMBL27147241 0.71 PLA2G10 (0.41) ALDH1A1KDM4EWNT1GSK3BDYRK1A
SCHEMBL3470166 0.71 PLA2G10 (0.41) ALDH1A1KDM4EWNT1GSK3BDYRK1A
SCHEMBL31140048 0.71 PPARG (0.53) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL24880642 0.71 PPARG (0.53) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL22636512 0.71 DRD2 (0.51) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL20818730 0.70 ADRB2 (0.42) TRPC5ALDH1A1POLBAURKATIPARP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 — — EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN TRPC5 1439/4885ALDH1A1 649/4885KDM4E 3899/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN TRPC5 1439/4885ALDH1A1 649/4885KDM4E 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback